In Q3 of fiscal 2026, the quarter ended Feb 28, 2026, Cannabis Bioscience International Holdings, Inc. used $14,597 of cash from operations, up 92.1% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Feb 28, 2026
|
Q3 FY2026
Feb 28, 2026
|
Q2 FY2026
Nov 30, 2025
|
Q1 FY2026
Aug 31, 2025
|
Q4 FY2025
May 31, 2025
|
Q3 FY2025 YTD
Feb 28, 2025
|
Q1 FY2025
Aug 31, 2024
|
Q4 FY2024
May 31, 2024
|
Q3 FY2024
Feb 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Operating cash flow |
-0
+25.5%
|
-0
+92.1%
|
-0
|
-0
-241.0%
|
-0
+17.3%
|
-0
-1941.8%
|
-0
|
-0
|
-0
|
| Investing | |||||||||
| Investing cash flow |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
| Financing | |||||||||
| Short-term debt issued |
—
|
—
|
—
|
—
|
—
|
—
|
-0
|
0
|
-0
|
| Financing cash flow |
0
-25.5%
|
0
-40.1%
|
—
|
—
|
0
-10.1%
|
0
+1841.8%
|
0
|
0
|
0
|
| Change in cash | |||||||||
| Net change in cash |
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
0
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- CBIH (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- CO
- Headquarters
- Yantis, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1411057
- Former names
- CHINA INFRASTRUCTURE CONSTRUCTION Corp (until Aug 24, 2022); FIDELITY AVIATION CORP (until Sep 15, 2009)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.